Very interesting. I wasn't aware of them. They already have FDA approval for HF and some reimbursement codes. The competitors are certainly out there. It's mainly the team and the relationships that EIQ appear to have with the leading hospitals that give me confidence they will execute.
Having said that we're overdue for some news imo.
I would love to hear any day now that they have secured a clinical study with Mayo Clinic for HF.
AU pilot program with leading manufacture - This was supposed to be in December. Crickets thus far.
First revenue with the Miscellaneous Code 93799 identified 9 December.
Hopefully these come to fruition soon and we don't have to wait until June+ for first revenue once they obtain cat 3 reimbursement codes.
EIQ Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)